John R. Desjarlais, Ph.D., is a distinguished figure in the field of biotechnology, currently serving as the Chief Scientific Officer at Xencor, Inc. Dr. Desjarlais earned his Ph.D. in Biochemistry from the University of California, Berkeley, and has since built an impressive career centered on protein engineering and therapeutic development. His expertise in these areas has been pivotal in advancing Xencor's mission to develop innovative antibody and cytokine therapeutics. Throughout his career, Dr. Desjarlais has been instrumental in the development of several groundbreaking therapeutic candidates. He has authored numerous peer-reviewed publications and holds multiple patents related to protein engineering and immunotherapy. His work has significantly contributed to the understanding of protein-protein interactions and the design of novel biologics, which has led to the advancement of multiple clinical programs at Xencor. As Chief Scientific Officer, Dr. Desjarlais oversees the company's research and development efforts, guiding the strategic direction of Xencor's pipeline and ensuring the continued innovation and success of its therapeutic programs. In his role at Xencor, Dr. Desjarlais is responsible for leading a team of scientists and researchers dedicated to discovering and developing new treatments for cancer and autoimmune diseases. His leadership has been crucial in fostering a collaborative and innovative environment at Xencor, driving the company's growth and its ability to bring new therapies to patients in need. Dr. Desjarlais's contributions to the field of biotechnology and his role at Xencor underscore his commitment to advancing medical science and improving patient outcomes.